Meeting Banner
Abstract #0619

Effects of Bevacizumab on the Tumor Vascularity Assessed with DCE-MRI in Recurrent Anaplastic Astrocytomas

Weiting Zhang1, Teri N. Kreisl1, Jeffrey Solomon2, Richard C. Reynolds1, Daniel R. Glen1, Robert W. Cox1, Howard A. Fine1, John A. Butman1

1National Institutes of Health, Bethesda, MD, United States; 2Medical Numerics, Inc., Germantown, MD, United States

DCE-MRI was used to monitor the effects of bevacizumab on physiologic measures of tumor vascularity, such as blood brain barrier permeability, represented as Ktrans , and vascular perfusion represented as fpv, in patiens with recurrent anaplastic astrocytoma. Bevacizumab dramatically reduces Ktrans, fpv, and enhancing tumor volume as early as 4 days and this effect persisted at least for 4 weeks. Tumors with larger baseline enhancing tumor volume and greater baseline Ktrans were related to poorer prognosis.